Myocardial function in patients with breast cancer after therapy with anthracyclines and chest irradiation

Journal of B.U.ON.

Volumn 12, Issue 3, 2007, Pages 349-352

  Radulescu, Dan ^a   Pripon, S ^a   Parv, A ^a   Duncea, C ^a   Ciuleanu, T E ^b   Radulescu, L I ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Institute of Oncology Prof Dr Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

Anthracyclines; Breast cancer; Doppler echocardiography; Left ventricular diastolic performance

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN;

A WAVE; ADULT; ARTICLE; BOLUS INJECTION; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HUMAN; RADIATION DOSE FRACTIONATION; RELAXATION TIME;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 35248858719     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Minotti G, Cavaliere AF, Mordente A et al. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron induced cardiotoxicity. J Clin Invest 1995; 95: 1595-1605.
2. Pereira RP, Fleck JF, Rohde LE et al. Superoxide dismutase activity in doxorubicin-induced cardiotoxicity in humans. Proc Am Soc Clin Oncol 2004; 22 (14S): 738s (abstr 8036).
3. Hudson MM, Rai SN, Deng H et al. Non-invasive evaluation of late cardiac toxicity in childhood cancer survivors. Proc Am Soc Clin Oncol 2004; 22 (14S): 530s (abstr 6047).
4. Valero V, Gill E, Paton V et al. Normal cardiac biopsy results following co-administration of doxorubicin, cyclophosphamide and trastuzumab to women with HER2 positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 22 (14S): 20s (abstr 572).
5. Lefrak E.A, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-314.
6. Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711-716.
7. Kilickap S, Barista I, Akgul E et al. Increased troponin-T level is associated with anthracyclines-induced diastolic dysfunction of the left ventricle. Proc Am Soc Clin Oncol 2004; 22 (14S): 890s (abstr 9722).
8. Massie BM, Shah NB. The heart failure epidemic. Curr Opin Cardiol 1996; 11: 221-226.
9. Schwartz K, Mercadier JJ. Molecular and cellular biology of heart failure. Curr Opin Cardiol 1996; 11: 227-236.
10. Sacrez A. Genetique des cardiomyopathies dilatees. Arch Mal Cœur Vaisseaux 1995; 88: 591-593.
11. Wagoner LE, Walsh RA. The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 1996; 11: 237-244.
12. Anversa P, Kajstura J, Olivetti G. Myocyte death and heart failure. Curr Opin Cardiol 1996; 11: 245-251.
13. Bristow MR. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 1978; 62: 873-879.
14. Kantrowitz NE. Cardiotoxicite des agents antitumoraux. Acquis Nouv Pathol Cardiovasc 1985; 27: 285-291.
15. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.
16. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2 positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
17. Piccart-Gebhart MJ, Proctor M, Leyland - Jones B et al. Trastuzumab after adjuvant chemotherapy in HER 2 positive breast cancer. N Engl J Med 2005; 353:1659-1672.
18. Giordano SH, Booser DJ, Murray JL et al. A detailed evaluation of cardiac toxicity: A phase II study of doxorubicin and one- or three-hour infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002; 8: 3360-3368.
19. ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
20. Ferrari E. Repercussions cardiaques de la chimiotherapie. Medicorama 1982; 295: 5-19.
21. Swain MM, Whaley FS, Ewer MS. Congestive heart failure of patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
22. Gustafsson F, Torp-Pedersen C, Burchardt H et al. Female sex is associated with a better long term survival in patients hospitalized with congestive heart failure. Eur Heart J 2004; 25: 129-135.
23. Lee PJ, Mallik R. Cardiovascular effects of radiation therapy: Practical approach to radiation therapy-induced heart disease. Cardiol Rev 2005; 13: 80-86.
24. Cittadini A. Subclinical cardiotoxicity by doxorubicin. Eur Heart J 1991; 12: 1000-1005.